Future Market Insights (FMI)' latest industry analysis shows that the global advanced therapeutics pharmaceutical outsourcing market is projected to increase from US$ 7,592.8 million in 2024. The market is projected to reach US$ 11,698.1 million, surging at a CAGR of 4.4% by 2034.

Advanced therapeutics encompass a range of cutting-edge and innovative treatments, including gene therapies, cell therapies, mRNA-based therapies, and other personalized and precision medicine approaches. Pharmaceutical companies often collaborate with external partners, such as contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) service providers, to leverage their expertise, infrastructure, and capabilities in the complex and rapidly evolving field of advanced therapeutics.

Request A Sample Copy of This Research Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-18755

The advanced therapeutics pharmaceutical outsourcing market is propelled by an array of drivers and opportunities that underscore its pivotal role in the dynamic landscape of advanced therapeutic development. Rapid advancements in gene therapy, cell therapy, and mRNA sequencing technologies are catalysts for outsourcing services, demanding specialized expertise to navigate their complexities. 

The escalating pipeline of innovative therapies, especially those targeting rare diseases and oncology, provides a fertile ground for outsourcing partners to offer indispensable support in development and manufacturing. The globalization of clinical trials, driven by the trend toward personalized medicine, particularly in oncology, further amplifies the demand for outsourcing services with a global reach.

Technological innovations in manufacturing, such as continuous manufacturing and automation, present opportunities for outsourcing partners to enhance efficiency and scalability in producing advanced therapeutics. Strategic collaborations and partnerships between pharmaceutical companies, academic institutions, and outsourcing entities foster innovation and collectively address challenges in the rapidly evolving field. 

As the market evolves, opportunities lie in expanding outsourcing services to cover a broader spectrum of advanced therapeutic modalities, meeting pharmaceutical clients' diverse and dynamic needs.

Key Takeaways from the Market Study:

  • By service type, contract development and manufacturing organizations (CDMOs) are expected to surge at a CAGR of surge at a CAGR of 3.7% by 2034.
  • By indication, oncology held a 46.1% market value share in 2023. 
  • By therapy, gene therapy held the leading share in the market of 49.6% in 2023. 
  • By phases, commercial manufacturing, and packaging segment dominates with the leading share, accounting for 54.9% in 2023. 
  • North America is the primary region, holding a substantial value share of 37.3% in 2023. 

"Development and manufacturing of advanced therapeutics, such as gene and cell therapies, is responsible for the growth of the advanced therapeutics pharmaceutical outsourcing market worldwide," Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Competitive Landscape:

The advanced therapeutics pharmaceutical outsourcing market encourages collaborative innovation, with pharmaceutical companies and outsourcing partners working together to advance technologies, overcome challenges, and bring novel therapies to market. 

For instance,

  • In June 2023, KD Pharma Group and DUDE CHEM announced their strategic partnership to usher in a new era of digital innovation, greatly enhancing the efficiency and safety of pharmaceutical drug and therapy development. 
  • In January 2021, Thermo Fisher Scientific, Inc. acquired the viral vector business from Henogen S.A (Groupe Novasep SAS).

Key Companies Profiled:

  • Croda International Plc
  • Charles River Laboratories International, Inc.
  • Catalent, Inc.
  • QuintilesIMS (IQVIA)
  • Parexel International Corporation
  • ICON plc
  • PPD, Inc. (Thermo Fisher Scientific)
  • LabCorp (Laboratory Corporation of America Holdings)
  • Syneos Health
  • WuXi AppTec
  • Lonza Group
  • Piramal Pharma Solutions
  • SGS SA
  • Evotec SE
  • CMC Biologics (Now AGC Biologics)
  • Marken (A UPS Company)
  • Cytovance Biologics
  • Samsung Biologics
  • CordenPharma
  • Recipharm AB
  • Vetter Pharma International GmbH
  • Cryoport Systems, Inc.
  • ProPharma Group
  • Fujifilm Diosynth Biotechnologies
  • Medpace
  • Novotech Pty Ltd.
  • Axcella Health Inc.
  • CelerionAshland

Advanced Therapeutics Pharmaceutical Outsourcing Industry Segmentation:

By Service Type:

  • Contract Research Organizations (CROs)
  • Contract Development and Manufacturing Organizations (CDMOs)

By Indication:

  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Others

By Therapy:

  • Cell Therapy
  • Gene Therapy
  • RNA-based Therapies
  • Others

By Phases:

  • Preclinical Services
  • Clinical Services
  • Commercial Manufacturing and Packaging

By Region:

  • North America
  • Latin America
  • East Asia
  • South Asia and Pacific
  • Western Europe
  • Eastern Europe
  • Middle East and Africa